Menu
Back to Journals » Drug Design, Development and Therapy » Volume 4
Original Research
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
| Total article views | Abstract views | HTML views | PDF downloads | Totals | |
|---|---|---|---|---|---|
| 15,935 | Dovepress* | 13,965 | 543+ | 1,905 | 14,508 |
| PubMed Central* | 20 | 1,407 | 554 | 1,427 | |
| Totals | 13,985 | 1,950 | 2,459 | 15,935 | |
|
*Since 15 November 2010 +Since July 2016 |
|||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 4 | 0 | 0 | 0 | 0 | 4 |
View citations on PubMed Central and Google Scholar